This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APTX Aptinyx (APTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aptinyx Stock (NASDAQ:APTX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Aptinyx alerts:Sign Up Key Stats Today's Range$0.09▼$0.1050-Day Range$0.06▼$0.1052-Week Range$0.01▼$0.72Volume231,100 shsAverage Volume1.32 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Read More… Remove Ads Receive APTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter. Email Address APTX Stock News HeadlinesAptinyx Inc Com (OTC:APTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comApple Watch X: All the Rumors So FarAugust 25, 2024 | macrumors.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 2, 2025 | Priority Gold (Ad)Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOApril 23, 2024 | businesswire.comNew Leaf Venture Management III, L.L.C.'s Net WorthMarch 12, 2024 | benzinga.comPatrick J Heron's Net WorthFebruary 9, 2024 | benzinga.comBest Noise-Canceling Headphones for 2024January 13, 2024 | cnet.comAptinyx Inc APTXDecember 17, 2023 | morningstar.comSee More Headlines APTX Stock Analysis - Frequently Asked Questions How were Aptinyx's earnings last quarter? Aptinyx Inc. (NASDAQ:APTX) posted its earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). When did Aptinyx IPO? Aptinyx (APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptinyx investors own include Plug Power (PLUG), Tesla (TSLA), Evofem Biosciences (EVFM), VBI Vaccines (VBIV), SCYNEXIS (SCYX), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). Company Calendar Last Earnings11/09/2021Today4/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APTX CIK1674365 Webwww.aptinyx.com Phone(847) 871-0377FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book0.17Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:APTX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | SponsoredNew “Trump” currency proposed in DCYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptinyx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptinyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.